2-[(2-Chloro-6-fluorophenyl)amino]-5-methylphenyl]acetic acid
Kidney Failure, Chronic
Hospital Central Sur de PemexSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
30 Active assets in the Kidney Failure, Chronic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
SODIUM FERRIC GLUCONATE Watson Pharmaceuticals | Phase 4 | BBB |
IRON(II) SULPHATE (1:1), HEPTAHYDRATE Watson Pharmaceuticals | Phase 4 | BBB |
Semaglutide Institute of Liver and Biliary Sciences, India | Phase 4 | BBB |
Plavix Hospital Alemão Oswaldo Cruz | Phase 4 | BB |
Acetylsalicylic Acid Hospital Alemão Oswaldo Cruz | Phase 4 | BB |
View all 50 →
Same molecule, other indications
2-[(2-Chloro-6-fluorophenyl)amino]-5-methylphenyl]acetic acid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →